Eric Lefkofsky is an incredible entrepreneur who co-founded a genomic sequencing company known as Tempus. Tempus mainly helps doctors customize cancer treatments to simplify diagnosis. Recently, the Chicago based company announced it had raised $ 70 million from New Enterprise Associates and investors Revolution Growth in its series C funding round. This funding is part of the total &130 million since it was started in 2015 with his co-founding partner Brad Keywell.
Mr. Eric Lefkofsky serves as the CEO of the company and together with Brad, and they have always invested in any fundraising that takes place. Eric spoke to Crain’s Chicago Business that he was willing to invest even up to $ 1000 million in Tempus. Most of the investors who also funded Tempus have also supported other companies. For example, New Investors NEA and Revolution Growth previously had funded stock trading app Robinhood and Sweetgreen respectively and many others. Last year Tempus announced it is partnering with the Mayo Clinic, Duke University and also with Cleveland Clinic and many others which was going to benefit their business of Tempus and also help many cancer patients
Eric Lefkofsky was into the tech industry, and so it shocked people when he decided to venture into the healthcare industry. Three years ago, a loved one to Eric was diagnosed with breast cancer, and during treatment, Eric noticed how there was an extreme scarcity of infrastructure in how data was being collected. Therefore the idea of Tempus was born where it uses technology to compile clinical and genomic data from cancer patients so that physicians can customize treatment.
Eric Lefkofsky is a native of Southfield in Michigan and was born on September 2, 1969. He moved to Chicago at a tender age and attended the University of Michigan where he earned honors and then later joined the University of Michigan, School of Law where he obtained a Juris Doctor.
His entrepreneurial skills started in college where he used to sell carpets, and now he has improved to a legendary in entrepreneurship. Moreover, Eric is a philanthropist, and with his wife, they established the Lefkofsky Foundation that supports organizations. Eric is positive about helping cancer patients.
Dr. Jennifer Walden, board-certified cosmetic surgeon, has been on the fast track to success for a number of years. At this point in time, she has made a positive name for herself and for her practice. Walden Cosmetic Surgical Center is one of the leading cosmetic surgical institutions in the U.S. Located in Austin, Texas, this institution specializes in a wide range of cosmetic services such as laser skin resurfacing, breast reduction, breast lift, cheek implants, eyelid lifts, forehead lifts, breast augmentation, dermabrasion, chemical/micro peels, lip augmentation, winkle reduction by injection and numerous others.
Walden Cosmetic Surgery Center is on another level when it comes to providing proper care, advice and guidance. This institution has a commitment to excellence, and it has thousands of satisfied clients to back up all claims. Walden is the queen of accomplishments thanks to her extensive educational background. She has been honored and awarded with numerous titles. She has a Medical Doctorate from the University of Texas Medical Branch as well as a B.A. in Biology from the University of Texas. While in New York City, she received her fellowship in aesthetic surgery from the prestigious Manhattan Eye, Ear and Throat Hospital. She also worked and resided in New York’s Upper East Side for seven years. In 2011, Walden moved back to her home state of Texas after her twin sons were born and more
Being such a male dominated industry, Walden has stated that she has to consistently prove herself in this demanding field. She has also stated that she is a liberal-feminist, and that she celebrates female empowerment. Dr. Jennifer Walden is basically doing what she loves, is earning a respectable salary, and she has single-handedly brought aspirations to other women who may be interested in following her footsteps.
Mikhail Blagosklonny is currently a professor of Oncology at Rosewell Park Cancer Institute located in Buffalo, New York and Chief Editor of Oncortarget. Blagosklonny has been for many years now at the forefront in researching cancer; its therapies and aging. He is famously known for spearheading the use of Rapamycin a cancer drug that helps increase the lifespan of human beings. Rapamycin is a drug that is commonly used for the prevention of organ transplant rejection. The drug which is also known as Sirolimus is used in the coating of coronary stents and the treatment of a rare lung disease. Rapamycin is also a popular cancer drug. The drug was previously used as an anti-fungal agent, but because of its immunosuppressive and antiproliferative properties, doctors stop using it as an anti-fungal agent.Rapamycin immunosuppressant properties play a very critical role when it comes to organ transplant. During organ transplant the body naturally tends to reject foreign organs. For an organ transplant to be successful doctors, recommend the use of anti-rejection drugs or immunosuppressive drugs. However, most of these drugs have adverse effects on the kidneys, and that’s where Rapamycin scores highly as compared to the other immunosuppressive drugs as it has very minimal toxicity level towards the kidney.
Rapamycin is also best for treating hemolytic-uremic syndrome a condition which results from a combination of anemia, kidney failure, and low platelet count. As a result, a patient suffering from the disease is required to have a kidney transplant where one has to use the immunosuppressive drugs to prevent organ rejection. The drugs due to its toxicity nature to the kidney may affect the new kidney thus the use of Rapamycin is recommended to lower the toxicity level. Another use of Rapamycin is in the treatment of Lymphangioleiomyomatosis (LAM) which is a rare lung disease that affects mature women. Also, the drug is used for coronary Stent coating where it prevents the occurrence of re-stenosis in the arteries after a balloon angioplasty procedure. The antiproliferative properties of Rapamycin are used in the treatment of cancer. The drug helps boost the body immune system towards tumors and promotes tumor regression thereby limiting cancer in patients with an organ transplant. Other uses of Rapamycin include the treatment of Tuberous Sclerosis Complex (TSC), Facial Angiofibromas, Muscular Dystrophy, Alzheimer, Systemic Lupus Erythematosus and increase in person’s longevity among others.
One particular area of interest for Mikhail Blagosklonny is the area of cancer as well as aging. Mikhail is interested in specifically knowing what the relationship between the two is as cancer mostly attacks individuals at old age. Mikhail continues to research the field of oncology with the aim of not only finding a way of treating cancer but also to find a method of treatment that will be affordable to many. In addition, Blagosklonny wants to figure out a way in which cancerous cells can be destroyed without affecting the normal cells that are crucial to recovery.Mikhail has made much progress in the field of medicine and cancer treatment and hopes that his findings will inspire others even to do more in the industry. Mikhail endeavors to see that the treatment of cancer is not a preserve of the wealthy in the society who can comfortably afford the treatment but instead it should be an easy and cost-effective type of treatment that is accessible to all regardless of an individual’s financial status.
Dr. Rick Shinto is the President and the Chief Executive Officer at InnovaCare Health. He had previously presided over Aveta International as the CEO before his appointment to InnovaCare. He has also worked at the NAMM Medical Center as the Chief Executive Officer. Rick served at the MedPartners from 1996 to 1997.
Some of the awards won by Dr. Shinto
In 2012, Dr. Rick Shinto was crowned at the Ernest and Young Entrepreneur of the Year Award, a tribute, and recognition for the selfless service he had demonstrated while at InnovaCare. He was also recognized by the Western University with the Access to Caring Award. Dr. Shinto has shown commitment to excellence, success, and innovation all his professional life.
Work experience of Penelope Kokkinodes
Kokkinodes Penelope was the Executive Vice President and the Chief Operating Officer at the CenterLight HealthCare. She was the chief strategist and the operations manager. Kokkinodes had also served as the Chief Operating Officer at the Touchstone Health and the Vice President of the Americhoice, a firm that deals with disease management.
Insights from an interview with Penelope Kokkinodes
Kokkinodes notes that technology and internet connectivity has made her work easy and similarly made it easy for clients. She has been able to reach out to people around the globe through several travels and international engagements. People should learn to embrace new technology. One travels less but has the capabilities of increasing rewards, a great revolution for this age.Kokkinodes also has something for entrepreneurs. She advises that they should take the time to learn trends in the industry developments. Entrepreneurs should learn new concepts, read articles, publications, books, and research materials, which will contribute acquisition of new ideas.
New executive at InnovaCare
Jonathan Meyers was appointed as the new Chief Actuary Officer of the InnovaCare Health. Mike Sortino was named to serve in the capacity of a Chief Accounting Officer. Penelope Kokkinodes has also been added as the new Chief Admin.
About InnovaCare Health
InnovaCare is a provider of private Medicare and Medicaid services in Puerto Rico. It also provides MMM Healthcare Services and Medicare and Medicaid Options like the PMC. InnovaCare Health has a total enrollment of 200,000 subscribers, who are served by a workforce of about 7,000 service providers. InnovaCare has been able to remain a leader in the provision of a payment model through the incorporation of the Government Health Plans of GHP.
“The Greater Effort toward Tomorrow’s Medical Horizon”
In addressing the National Medical Association, William J. Mayo spoke concerning the ideals and aims of the American Medical Association. Emphasizing the practice of medicine is patient’s benefit, he said, “The glory of medicine is that it is constantly moving forward, that there is always more to learn. The ills of today do not cloud the horizon of tomorrow, but act as a spur to greater effort.”
Creating partnerships with medical healthcare industries worldwide, a prosperous entrepreneur, Eric Lefkofsky pursues life-changing work of transforming cancer patient outcomes with innovative treatment decisions by delivering clinically serviceable diagnostics. His mission utilizes genomics, a division of biotechnology through the application of genetics and molecular biology to the mapping of genetics and DNA sequencing of gene sets. As a generous philanthropist, he has established charitable trust called the Lefkofsky Foundation, promoting the support of scientific, charitable, and educational organizations and causes around the globe.
“Redefining Genomic Clinical Data- Personalizing the Approach”
Eric Lefkofsky co-founded Tempus, a technology platform connecting molecular and anatomic data with clinical data from worldwide medical institutions, which personalizes the approach in battling cancer. As the CEO, Eric Lefkofsky has the objective of improving patient outcomes, providing physicians with implements that acquire learning techniques through data technology application for clinical care, delivering on the genomics promise. The aim is for every patient to benefit from other previous patient treatments.
“Challenging the Status Quo through Unwavering Commitment”
Eric Lefkofsky trusts that Tempus can become the Therapeutic Holy Grail, perceiving that, “The aim of medicine is to prevent disease and prolong life, the ideal of medicine is to eliminate the need of a physician.” Through his avid philanthropy and brilliant education, Eric Lefkofsky possesses a motivated commitment toward conveying applicable technology toward cancer, with the ultimate goal of applying this knowledge to treatment in attacking the most challenging medical problem known to man on our planet today.
About Eric Lefkofsky: norcal.news/news/23733-eric-lefkofsky-searches-coast-coast-cure
Simply defined, Medicare Advantage plans are a form of health insurance, which is passed from Medicare to beneficiaries through private insurance companies that are approved by Medicare. The plans offer both parts A and B and are customized to allow users to choose those what best matches with their needs.
Medicare Advantage plans may differ in costs and regulations depending on the region and company you choose. This is like a free platform that cannot be fully regulated by the federal government, so when choosing a plan you need to understand the terms, and, if possible, ask questions.
People want to know the differences between Original Medicare and Medicare advantage. These plans are not very different as there are many similarities that differences. Both have the Part A and B plans and are health insurance plans that enhance cost-effectiveness and convenience in the health system.
What are disadvantages of Medicare Advantage plans?
Owing to the fact Medicare Advantage plans are provided through private companies, there are bound to be disparities in guidelines. The specifics contained in a plan are dependent on the insurance company offering the same. Consequently, you may need high out-of-pocket costs for your plan if you compare it with Original Medicare. Also note the insurance company demands you follow strict rules, failure to which you may lose your right for compensation.
Who qualifies for enrollment to a Medicare Advantage plan?
To be eligible for a Medicare Advantage plan, you need to first enroll in Parts A and B Medicare. Those suffering from end-stage renal disease generally lose eligibility for this type of plan. You also need to ensure you live within the service area in which your preferred Medicare plan is offered.
About InnovaCare Health
InnovaCare Health is a Puerto Rico based managed healthcare provider specializing in Medicare Advantage and physician practices. The company is committed to offering high-quality healthcare solutions by coming up with cost-effective procedures that are run through sustainable models. InnovaCare has tried to integrate most of its services with advanced technologies to enhance service delivery and quality of care.
Dr. Richard Shinto, M.D.,MBA, the CEO of InnovaCare Health, is an important member of the company as his support has gone a long way into ensuring InnovaCare achieves growth and expands its addressable market. Author of clinical medicine articles and a B.S. graduate from the University of California, Dr. Rick Shinto brings to the company exceptional skills and massive experience.
The Chief Administrative Officer of InnovaCare, Penelope Kokkinides, can also be celebrated for ensuring InnovaCare is run seamlessly through modern and focused ideas. She has worked with different companies before including Aveta Inc., and she offers over 20 years experience and great management skills.
Nobilis Health Corporation utilizes a unique direct to patient marketing that is focused on a set of procedures that are performed at our centers by local physicians. Nobilis Health Corporation owns and manages ambulatory and care buildings to deliver health care services. Nobilis owns and manages interests in surgery centers in Texas and Arizona. In addition, Nobilis has an acute care hospital, two imaging centers, and an urgent care clinic in Houston Texas. Nobilis Health Corporation, a health care facility management and marketing firm announced that it closed a debt financing facility with GE Capital Healthcare Financial Services. The facility will be used to support Nobilis’ growth efforts provide a new line for working capital, as well as repay certain parts of the company’s existing indebtedness, most notably money attached to the Athas Health acquisition. The transition was a goal for Nobilis Health. The company wanted to reduce their average borrowing costs while maintaining structure. Nobilis Health also believes that their new relationship with GE Capital will provide momentum for Nobilis’ growth in future years. The company has flexible capital programs to help customers expand their companies. GE Capital’s Healthcare Financial Services business is one of the top capital providers in the United States. Customers across all 45 health care sectors use Healthcare Financial Services to help fiance acquisitions, refinance existing debt, and help with growth. The different sectors include senior housing, medical offices, hospitals, and medical devices. The funding of the building includes two different loans; one for $20 million and one for $5 million